Nvelop Therapeutics

Today, we celebrate a transformative milestone as the exceptional teams at @chromamedicine and @nvelop_tx unite to form nChroma Bio. Together, we are embarking on a shared mission to redefine the future of genetic medicines. Stay tuned for what’s next and be sure to follow us @nchromabio.

On Friday, October 25th, Nvelop will deliver an oral presentation at the 31st Annual @ESGCT Congress. Showcasing the latest preclinical data on DLVR-M, this presentation will further demonstrate the programmability and in vivo validation of our novel delivery platform. Read more: ow.ly/mVfi50TQBHU

Today, at the American Society of Gene & Cell Therapy @ASGCTherapy annual conference, Nvelop Therapeutics will share the first preclinical data from our novel DLVR-M platform, created by gene editing pioneer Keith Joung, M.D., Ph.D. and his team at Mass General Hospital. See today's announcement here: ow.ly/2ZUi50RAeqV

We are pleased to introduce Nvelop’s Scientific Advisory Board, a distinguished group of leaders from the fields of gene therapy, gene editing, and drug delivery. Read more: ow.ly/G0vh50RuGvi

Today, we announced the official launch of Nvelop Therapeutics, a company created to overcome the challenges of in vivo delivery for the next generation of genetic medicines. Read more: ow.ly/CBhs50Rbf0Q